Evidence map›Paper›PMID 30232604›Full record

ArticleInfection2019

Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.

Emanuela Zappulo, Laura Ambra Nicolini, Carmen Di Grazia, Alida Dominietto, Teresa Lamparelli, Francesca Gualandi, Patrizia Caligiuri, Bianca Bruzzone, Emanuele Angelucci, Claudio Viscoli and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Emanuela ZappuloDivision of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy.
Laura Ambra NicoliniDivision of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy.
Carmen Di GraziaDivision of Hematology and Bone Marrow Transplantation, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Alida DominiettoDivision of Hematology and Bone Marrow Transplantation, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Teresa LamparelliDivision of Hematology and Bone Marrow Transplantation, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Francesca GualandiDivision of Hematology and Bone Marrow Transplantation, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Patrizia CaligiuriDepartment of Health Sciences, University of Genoa, Genoa, Italy.
Bianca BruzzoneHygiene Unit, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Emanuele AngelucciDivision of Hematology and Bone Marrow Transplantation, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.
Claudio ViscoliDivision of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy.
Malgorzata MikulskaDivision of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy. m.mikulska@unige.it.
Ospedale Policlinico San Martino · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHepatitis B virus (HBV) reactivation during immunosuppressive therapy is common in patients with hematological malignancies, even in case of resolved infection. Prophylaxis of HBV reactivation is universally recommended in stem cell transplant (SCT) recipients and patients treated with anti-CD20 agents (i.e., rituximab). Despite its well-established favorable safety profile, lamivudine (LAM) use in prophylaxis has been debated because of the possible emergence of resistant viral strains. The aim of this study was to investigate the efficacy of LAM in preventing HBV reactivation in allogeneic SCT recipients with a resolved HBV infection.

methodsPatients who received first allogeneic SCT in years 2009-2016 were evaluated. Sixty-three patients with resolved infection received LAM prophylaxis and were included in the study. Baseline and post-SCT characteristics were recorded, including rituximab exposure, length of LAM prophylaxis, and time from transplant to the last clinical and virological follow-up.

resultsOverall, 39 patients (62%) were male, 39 (62%) had acute myeloid leukemia, 38 (60%) received transplant from haploidentical donor, 29 (53%) received myeloablative conditioning, and 15 (24%) received rituximab post-transplant. Median clinical follow-up was 24 months after SCT (range 0.3-97); median virological follow-up 16 months (range 0.3-78), and median length of LAM prophylaxis of 14.5 months (range 0.3-78). No patient experienced HBV reactivation while on LAM prophylaxis. One patient experienced reactivation 8 months after discontinuing prophylaxis.

conclusionsIn this high-risk population, LAM prophylaxis was effective in preventing HBV reactivation in patients with resolved infection. It should be considered a reasonable first-line prophylactic agent to be administered in this setting.

Indexed as

Antibiotic ProphylaxisStem Cell TransplantationAdultAgedAntiviral AgentsFemaleHematologic NeoplasmsHepatitis BHepatitis B virusHumansItalyLamivudineMaleMiddle AgedRituximabVirus ActivationAntiviral AgentsLamivudineRituximabAnti-CD20HBcAbHBVHematologicalLAMTransplant

Identifiers

PMID30232604
OpenAlexW2891107132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.